Edward T. Mathers, who holds a 10 percent stake in Korro Bio, Inc. (NASDAQ:KRRO), executed a material purchase of the company’s equity on March 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows Mathers bought 207,100 shares of Korro Bio common stock at $11.11 per share, an outlay totaling $2,300,881. In the same transaction he also acquired 242,945 Pre-Funded Warrants priced at $11.109 each. The deal occurred as KRRO shares were trading near $11.50, after a year-to-date rebound of 44 percent but following a 63 percent decline over the previous six months.
The timing of the insider purchase is notable: Korro Bio has an earnings announcement scheduled for March 18, several days after the reported transactions. The Form 4 filing documents the insider activity but does not provide additional commentary on Mathers’ rationale.
Separate corporate developments over the same period provide additional context for investor interest. Korro Bio announced an $85 million private investment in public equity financing, led by Venrock Healthcare Capital Partners with participation from ADAR1 Capital Management and Affinity Asset Advisors. The financing round was disclosed by the company and represents a sizeable capital infusion.
Analyst coverage of Korro Bio shifted more positive following the company’s Analyst Day presentation. Clear Street moved its rating from Hold to Buy, citing the potential of KRRO-121 to treat hyperammonemia. H.C. Wainwright upgraded the stock from Neutral to Buy, calling out KRRO-121 as a liver-targeted RNA editing drug. Piper Sandler raised its view to Overweight, emphasizing the candidate’s potential relevance for Urea Cycle Disorders and Hepatic Encephalopathy. These upgrades were linked explicitly by the firms to the prospects of KRRO-121 and to the material developments presented at Analyst Day.
Taken together, the insider purchase, the PIPE financing, and multiple analyst upgrades illustrate heightened market attention on Korro Bio and its lead clinical program. The Form 4 filing provides a record of the timing and size of the insider transaction, while the financing and analyst actions offer broader signals of investor and research interest in the company’s drug-development plans.
Investors seeking additional analysis of Korro Bio’s financial position and market context may consult available platform-based research and tips referenced by market services that track the company. The SEC filing and the company’s financing disclosure are the primary sources for the transactions and capital raise summarized above.